In Vitro Binding of L-Triiodothyronine to Receptors in Rat Liver Nuclei

**KINETICS OF BINDING, EXTRACTION PROPERTIES, AND LACK OF REQUIREMENT FOR CYTOSOL PROTEINS**

**MARTIN I. SURKS, DIONA H. KOERNER, AND JACK H. OPPENHEIMER**

*From the Endocrine Research Laboratory, Division of Endocrinology, Department of Medicine, Montefiore Hospital and Medical Center, and the Albert Einstein College of Medicine, Bronx, New York 10467*

**ABSTRACT** Isolated hepatic nuclei from euthyroid rats were incubated with tracer [\(^{131}I\)]L-triiodothyronine (T₃) and increasing doses of nonradioactive T₃ for 30 min at 37°C. The T₃ bound specifically to nuclear sites increased with increasing T₃ doses to a plateau, which represented the nuclear binding capacity, M. Addition of 1 mM KCN, NaF, dinitrophenol, or iodoacetate did not affect nuclear binding, indicating that active metabolism was not required. Kinetic studies showed that the nuclear sites were equilibrated with T₃ within 30 min of incubation (one-half maximal binding at 3 min) and that the rate of release of T₃ in vitro (0.058 min⁻¹) was the same for endogenous T₃ or for T₃ bound to nuclei in vitro. Nuclear T₃ resisted extraction with 0.14 M NaCl buffered at pH 7.5, but both endogenous hormone and T₃ bound in vitro were readily extracted by 0.4 M KCl at pH 8.0. The elution profiles of endogenous and in vitro-bound T₃ from Sephadex G-100 columns showed a common protein peak with a molecular weight of 60-65,000, assuming a globular protein. Scatchard analysis of in vitro displacement studies showed a single class of binding sites. Mean M = 0.23 × 10⁸ M⁻¹ or 0.85 ng T₃ for nuclei isolated from 1 g of liver. Mean M closely corresponded to that anticipated from reported in vivo studies. The apparent association constant Kₐ for the nuclear sites, 5.55 × 10⁶ M⁻¹, was lower than in studies in vivo, probably attributable to the different ionic milieu of nuclei in the incubation buffer and in the intact cell. Thus, the identity of the nuclear T₃ binding sites studied in vitro to those reported for endogenous hormone is demonstrated by similar binding capacities, release rates, analogue binding affinities (previously reported), and localization to chromatin nonhistone proteins of comparable molecular weight. The role of cytosol protein in nuclear binding was assessed by comparing binding parameters for extensively washed nuclei and nuclei incubated either with contaminating or added cytosol. No difference in Kₐ or M was found. Moreover, it was unlikely that specific cytosol proteins were already present in nuclei and functioned during incubation as a shuttle for T₃, since Kₐ and M for nuclei obtained from athyreotic rats were similar to Kₐ and M for nuclei from euthyroid animals. Thus, an initial interaction between T₃ and specific cytosol proteins does not appear to be a prerequisite for translocation of T₃ to nuclear sites.

**INTRODUCTION**

Using in vivo displacement techniques, we have demonstrated the presence of limited-capacity binding sites for L-triiodothyronine (T₃) in the nuclei of rat liver and kidney (1). T₃ bound to hepatic nuclear sites exchanged rapidly with T₃ in the cell cytosol (2). These techniques thus allowed measurement of the nuclear binding capacity (M) for T₃ as well as the apparent association constant of the hepatic nuclear sites. Several lines of evidence suggest that the nuclear sites represent the

---

Dr. Surks is the recipient of Research Career Development Award KO4 AM 19502-01A.

Received for publication 17 June 1974 and in revised form 13 September 1974.

### Abbreviations used in this paper: HSA, human serum albumin; M, nuclear binding capacity; T₃, L-triiodothyronine; T₄, L-thyroxine.
cellular receptors for thyroid hormones and that binding of T₄ to these sites is a prerequisite for the expression of hormonal activity: First, the nuclear sites appeared relatively specific for T₄, since L-thyroxine (T₃) was bound to a much lesser degree. The apparent association constant (Kᵣ) of the nuclear sites for T₄, 4.7 × 10⁶ M⁻¹, was estimated to be about 20-fold greater than that of T₃ (2). Second, in vivo competition studies of various analogues of iodosyrosines and iodothyronines and of T₄ for the nuclear sites of both liver and heart showed that when analogue distribution and metabolism were considered, the displacement activities of the analogues were closely correlated with their reported thyromimetic activities (3). Third, examination of T₄ binding to nuclei of a number of rat tissues showed limited-capacity sites with Kᵣ similar to that of liver in all tissues studied (4). Moreover, there was a good correlation between tissue M and its reported biological response to thyroid hormones. For example, the M of spleen and testis, tissues considered unresponsive to thyroid hormones, were substantially less than those of liver, kidney, heart, and anterior pituitary. Fourth, studies of the intranuclear distribution of T₄ showed that the limited-capacity binding sites were localized to the chromatin fraction (5). The binding sites were further characterized as chromatin-associated nonhistone proteins. The identification of the T₄ nuclear receptors as nonhistone chromatin proteins is of special interest, since this class of nuclear proteins is considered intimately related to the control of DNA transcription (6). Moreover, some of the earliest detectable cellular biochemical changes that follow T₄ administration are the augmentations in DNA-dependent RNA polymerase activity and the rate of nuclear RNA synthesis (7).

These observations have been confirmed in part by DeGroot and Strausser (8) in rat studies, and Samuels and Tsai have demonstrated limited binding capacity nuclear sites for iodothyronines in pituitary GH₃ cells in tissue culture (9) and in intact lymphocytes (10).

More recently, we have demonstrated limited-capacity, high-affinity binding of T₄ to isolated rat liver nuclei in vitro (11). Binding of T₄ to limited-capacity nuclear sites in vitro has been separately reported by Samuels and Tsai (9, 12). Our preliminary observations have indicated that the nuclear sites demonstrated in vitro have similar characteristics to those previously described in vivo studies (2, 3). The present report describes the kinetics of binding and the extraction properties of T₄ bound to the nuclear receptor sites in vitro. In addition, data are presented that suggest that cytosol proteins are not required for effect the translocation of T₄ from cytosol to the nucleus.

METHODS

Male Sprague-Dawley rats, weighing between 150–200 g, were obtained from Carworth Div., Becton, Dickinson & Co., New City, N. Y., and maintained on a Wayne Laboratory rat diet (Allied Mills, Inc., Chicago, Ill.) (1 μg iodine/g) and tap water ad lib. In several experiments athyreotic animals were used. Surgical thyroidectomy was performed by the supplier. On receipt in the laboratory, thyroidectomized animals were placed on Low Iodine Test Diet fortified with vitamins (Nutritional Biochemical Corporation, Cleveland, Ohio) for 2 wk and then injected i.p. with 100 μCi of [³²I]sodium iodide. Body weight was measured twice a week, and the animals were considered athyreotic only after their body weights had remained constant for 3 wk. The serum T₄ concentration of these rats was undetectable (less than 2 ng/100 ml) as measured by radioimmunoassay (13).

Methods for the preparation of the nuclei have been detailed in previous reports (2, 14). After centrifugation through 2.2 M sucrose and 3 mM MgCl₂, the nuclear pellet obtained contained highly purified nuclei, as demonstrated by electron microscopy (average protein/DNA ratio was 1.84; average RNA/DNA ratio was 0.36). The nuclei were resuspended in 4 ml of 0.32 M sucrose and 3 mM MgCl₂ so that 1 ml of the nuclear suspension contained nuclei recovered from 1 g of liver. These nuclear suspensions were called unwashed nuclei.

Nuclei were further purified in several experiments to remove the small amount of cytosol protein (see Results) that might contaminate the nuclear pellet. The resuspended nuclei were centrifuged at 700 g for 10 min. The pellet was again suspended in 4 ml of 0.32 M sucrose and 3 mM MgCl₂ and centrifuged at 700 g for 10 min. This procedure was carried out once more, and the resulting nuclei were suspended in 4 ml of 0.32 M sucrose and 1 mM MgCl₂ (nuclei recovered from 1 g liver per ml). These preparations were called washed nuclei.

Cytosol was obtained by centrifugation of the initial 700 g supernate at 130,000 g for 60 min in a Spinco 40 angle rotor (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.).

Incubation of the nuclei was carried out as follows: T₄ labeled either with [³²I] (sp act, 33 μCi/nM), or with [³²I] (sp act 28 μCi/nM) was obtained from Abbott Laboratories, North Chicago, Ill. [³²IT₄] was added to 0.2 M Tris buffer, pH 7.0, at a concentration of 10 pmol/ml. Human serum albumin (HSA) (Albustein, Abbott Scientific Products Div., Abbott Laboratories, South Pasadena, Calif.) was added where indicated (0.3 or 3%). A series of tubes containing various concentrations of T₄ was then prepared by adding appropriate quantities of nonradioactive T₄ (free acid, Sigma Chemical Co., Inc., St. Louis, Mo.), dissolved in 0.1 N NaOH. 0.2 ml nuclear suspension, equivalent to nuclei from 200 mg of liver, was then incubated with either tracer T₄ solutions alone or with increasing amounts of nonradioactive T₄ in a volume of 1 ml incubation medium. The final concentration of the constituents of the incubation medium were: T₄, 1–10,000 pmol/ml in 0.32 M sucrose, 3 mM MgCl₂, 20 mM Tris, and 1 mM NaOH, pH 7.0, at 37°C (incubation medium) in a total volume of 1 ml. The incubations were generally carried out for 30 min at 37°C, after which 1 ml of 1% Triton X-100 (Rohm and Haas Co., Philadelphia, Pa.) in 0.32 M sucrose and 3 mM MgCl₂ was added. After standing on ice for 15 min, the nuclei were recovered by centrifugation at 10,000 g for 10 min. The supernate was removed by gentle suction, and the counting...
The rate of the nuclear pellet was determined in a Packard Auto-gamma Spectrometer (Packard Instrument Co., Inc, Downer's Grove, III.). Sufficient counts were accumulated to limit counting error to less than ±5%. Measurements of the percent of incubated $[^{35}S]$T$_3$ bound to the Triton X-100-treated nuclei were performed in triplicate at each dose of T$_3$ incubated.

To examine the nature of the $[^{35}S]$T$_3$ bound to the nuclear sites in vitro, nuclear T$_3$ was extracted with either 0.14 M NaCl buffered with 0.01 M Tris at pH 7.5, or 0.14 M KC1 in 0.01 M Tris and 0.001 M EDTA, at pH 8.0. After incubation with $[^{35}S]$T$_3$, the nuclei were pelleted by centrifugation for 10 min at 10,000 g and then suspended by gentle homogenization into 2 ml of the indicated salt solutions. After 30 min at 0°C, the nuclei were pelleted by centrifugation at 10,000 g for 5 min. The supernate was removed and the nature of the radioactivity was examined by Sephadex gel filtration. Two different-sized columns were employed. To determine whether the extracted $[^{35}S]$T$_3$ was protein-bound or free hormone, 0.5 ml of the 0.14 M NaCl or the 0.4 M KC1 extracts were applied to 5 ml Sephadex G-50 medium columns (1.2 x 5.5-cm) equilibrated with the same buffer used for extraction. 1-ml fractions were collected. Protein-bound $[^{35}S]$T$_3$, eluted at the void volume, and nonprotein-bound $[^{35}S]$T$_3$ was recovered somewhat after the total column volume. Recovery of the applied radioactivity was 80-110%. The 0.4 M KC1 extracts were studied further by filtration on large columns of Sephadex G-100. The columns (100 x 1.3-cm) with a total vol of 90-100 ml were packed with Sephadex G-100 equilibrated with 0.4 M KC1, 0.01 M Tris, 0.001 M EDTA, and 0.1% sodium azide, pH 8.0, and then washed extensively with the same buffer. 0.5-1 ml of the nuclear 0.4 M KC1 extracts were applied. The flow rate was maintained at 15 ml/h. Fractions of 1.3 ml were collected, and the elution profile of radioactivity was compared to that of dextran blue (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) and proteins with known molecular weights (Schwarz/Mann Div., Becton, Dickinson & Co., Orangeburg, N. Y.).

Analytical procedures were as follows: DNA was determined by the method of Burton (15) with calf thymus DNA (Sigma Chemical Co.) as a standard; proteins were measured by the method of Lowry, Rosebrough, Farr, and Randall (16), with bovine serum albumin as a standard. Equilibrium dialysis was carried out as described previously (17). The nature of the radioactivity in various preparations was assessed by paper chromatography on Whatman 3 MM paper in a tert-amyl alcohol: 2 N NH$_4$OH: hexane solvent system. Details of the methods are reported elsewhere (18).

**RESULTS**

**Characteristics of the in vitro incubation system.** After incubation of isolated liver nuclei with tracer $[^{125}I]$T$_3$ (1-2 pmol/ml) 6-14% (35 experiments) of the incubated $[^{125}I]$T$_3$ was recovered in the Triton X-100-washed nuclear pellet. When increasing amounts of nonradioactive T$_3$ were incubated, a progressive decrease in the percentage of bound $[^{125}I]$T$_3$ was observed. In the representative experiment shown in Fig. 1, the percentage of $[^{125}I]$T$_3$ bound to nuclei incubated with tracer $[^{125}I]$T$_3$, 6.8, progressively decreased to a nadir of 1.8 when the nuclei were incubated with 300 pmol/ml T$_3$. Since incubation with higher concentrations of T$_3$ (3,000 or 30,000 pmol/ml) did not result in a further decrease in the percentage of $[^{125}I]$T$_3$ bound, the 1.8% value was considered to represent non-specific binding and was subtracted from the percentage of $[^{125}I]$T$_3$ bound at the lower ligand concentrations. The corrected percentage of $[^{125}I]$T$_3$ bound was considered equivalent to $[^{125}I]$T$_3$ specifically bound to the nuclei. The product of the specific percent $[^{125}I]$T$_3$ bound and the total T$_3$ incubated represents T$_3$ specifically bound to nuclear sites. When

![Figure 1](image_url)

**Figure 1** Displacement of tracer $[^{35}S]$T$_3$ bound to isolated hepatic nuclei by increasing amounts of nonradioactive T$_3$. Hepatic nuclei incubated with tracer $[^{35}S]$T$_3$ (1 pmol/ml) and increasing amounts of nonradioactive T$_3$ (up to 30,000 pmol/ml). The percentage of $[^{35}S]$T$_3$ falls progressively with increasing T$_3$ doses and reaches a nadir of 1.8% at 300 pmol/ml. Greater doses of T$_3$ incubated did not further reduce the percentage of $[^{35}S]$T$_3$ bound.

![Figure 2](image_url)

**Figure 2** Specific binding of T$_3$ by isolated hepatic nuclei. Data are taken from the experiment illustrated in Fig. 1. The percent total binding of $[^{125}I]$T$_3$ minus the percent $[^{125}I]$T$_3$ bound nonspecifically (1.8%) was equivalent to the percent specific $[^{125}I]$T$_3$ binding. The percent specific $[^{125}I]$T$_3$ bound multiplied by total T$_3$ incubated was equal to T$_3$ bound specifically to nuclei. The plot shows that T$_3$ bound specifically to nuclear sites increases with increasing T$_3$ doses incubated until a plateau is reached that represents the maximum binding capacity, M, of the incubated nuclei.

M. I. Surks, D. H. Koerner, and J. H. Oppenheimer
plotted as a function of the total Ts in the incubation mixture (Fig. 2). Ts bound specifically to nuclear sites approaches a plateau that represents the binding capacity, M, of the nuclear sites. Thus, as in previously reported in vivo studies (2), the binding of Ts to isolated nuclei in vitro is characterized by a well-defined binding capacity.

To examine further the characteristics of binding of Ts to isolated nuclei, experiments were first carried out to study the stability of the in vitro system. Fig. 3 shows a time course of nuclear Ts binding after incubation of both tracer (1 pmol/ml) and a molar excess (3,072 pmol/ml) of [125I]Ts. With the molar excess of [125I]Ts, approximately 1% of the incubated hormone was bound nonspecifically at all time intervals examined. After correction for nonspecific binding, the percentage of [125I]Ts specifically bound increased from 0.4 at 1 min of incubation to 4.9 at 10 min. Thereafter, the percentage of [125I]Ts specifically bound remained between 4.3 and 4.7 through the 60 min of incubation. Thus, binding to specific nuclear sites as well as nonspecific sites appeared relatively constant for 60 min of incubation. In other studies, however, (Table I) in which nuclear suspensions were preincubated for either 30 or 45 min at 37°C before addition of tracer or loading doses of [125I]Ts, there appeared to be a moderate decrease in the binding of tracer [125I]Ts with increasing time of preincubation. Nonspecific binding remained essentially unchanged. Specific binding decreased, from 4.28% for nuclei not preincubated, to 3.50 and 2.93% for nuclei preincubated at 37°C for 30 and 45 min, respectively, before incubation with [125I]Ts.

In incubations of isolated nuclei recovered from 0.2 g liver in 1 ml 0.32 M sucrose, 0.02 M Tris, 3 mM MgCl₂, 0.03% human serum albumin, pH 7.0, with tracer [125I]Ts, 1.54 pmol/ml and a loading dose [125I]Ts, 3,000 pmol/ml. Specific binding was calculated as the percentage binding at tracer dose (total binding minus the percentage binding at loading dose (nonspecific binding). Metabolic inhibitors were added at concentrations of 10⁻³ M. All flasks were incubated for 30 min at 37°C after addition of [125I]Ts. Each enzyme represents the average of three determinations.

The possibility that the modest decrease in specific nuclear binding with increasing time of incubation was due to a requirement for active metabolism and that essential metabolic substrates might be depleted during prolonged incubation appeared to be excluded, since addition of different metabolic inhibitors did not affect nuclear Ts binding significantly (Table I). Since the cause of the moderate decrease in nuclear binding during prolonged incubation was not determined, the duration of incubation in all subsequent studies was limited to 30 min.

To determine whether specific binding was proportional to the number of nuclear sites in the incubation mixture, increasing volumes of the nuclear suspension were incubated with either tracer or a molar excess of [125I]Ts (Fig. 4). An increase in the percentage of [125I]Ts bound was observed for both tracer and loading doses. The [125I]Ts bound specifically was proportional to the concentration of nuclei incubated.

**Kinetics of nuclear binding of Ts in vitro.** The time course of specific nuclear Ts binding is illustrated in Fig. 3. Whereas nuclear binding appeared to plateau at 10 min in this experiment, the percentage of [125I]Ts specifically bound to nuclei generally increased rapidly for 10 min, more slowly for 20–30 min, and occasionally declined gradually during the next 30 min (see Fig. 5). One-half maximal binding was attained at approximately 3–5 min of incubation.

---

**Table I**

<table>
<thead>
<tr>
<th>Preincubation</th>
<th>Additions</th>
<th>Tracer dose</th>
<th>Loading dose</th>
<th>Specific binding of [125I]Ts (total %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>min</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>—</td>
<td>6.42</td>
<td>2.14</td>
<td>4.28</td>
</tr>
<tr>
<td>30</td>
<td>—</td>
<td>5.42</td>
<td>1.92</td>
<td>3.50</td>
</tr>
<tr>
<td>45</td>
<td>—</td>
<td>4.82</td>
<td>1.89</td>
<td>2.93</td>
</tr>
<tr>
<td>60</td>
<td>KCN</td>
<td>6.12</td>
<td>1.84</td>
<td>4.28</td>
</tr>
<tr>
<td>70</td>
<td>NaF</td>
<td>6.36</td>
<td>1.89</td>
<td>4.47</td>
</tr>
<tr>
<td>80</td>
<td>Dinitrophenol</td>
<td>6.84</td>
<td>1.87</td>
<td>4.97</td>
</tr>
<tr>
<td>90</td>
<td>Iodoacetate</td>
<td>6.75</td>
<td>1.85</td>
<td>4.90</td>
</tr>
</tbody>
</table>

---

**Triiodothyronine Binding to Nuclear Receptors in Vitro**
before the animals incubation terminated both at 2-min nuclear excess molar.

Specific medium.

specifically in vitro, the specific release rate of [\(^{3}I\)]T_{s} from harvested nuclei (0.4 pmol/ml). Incubation mixtures were sampled at 2-min intervals to determine specific nuclear binding. At 9.5 min of incubation, the mixtures were divided. A molar excess of T_{s} (3,000 pmol/ml) was added to one portion to prevent detectable further nuclear binding of [\(^{3}I\)]T_{s} from the incubation medium, and the vehicle in which the loading dose was dissolved was added to the other portion. The curves in Fig. 5 show that the release rate of nuclear T_{s} was the same for endogenous T_{s} (t_{1} = 14.0 min) as for T_{s} bound to specific nuclear sites in vitro (t_{1} = 14.5 min). The lack of significant change in the maximal percentage of [\(^{3}I\)]T_{s} bound specifically in vitro when vehicle was added indicated that the vehicle did not perturb the system. In two other experiments, similarly designed, the t_{1} of release of nuclear T_{s} was 10.0 and 12.2 min. The similarity in the rates of release in vitro of T_{s} bound to the nuclear sites in vivo and in vitro provides further evidence that T_{s} binding to isolated nuclei occurs at the same sites as previously reported in studies in vivo.

The average t_{1} of 12 min for T_{s} bound to nuclear sites also allows estimation of the effect of endogenous T_{s} released from the nuclei upon subsequent calculations.

As determined by in vivo displacement studies (4), the mean M is 1.77 ng T_{s} for nuclei derived from 1 g of liver (2.72 pmol/g). In euthyroid rats, the mean percentage saturation of these sites is 47% (4), and the mean recovery of nuclei based on DNA measurements is 59%.

Thus, the nuclear suspensions used in these studies contain approximately 0.151 pmol T_{s}/0.2 g liver nuclei (2.72 × 0.47 × 0.58 × 0.2). Based on the observed release rates, the main portion (82%) of the endogenous T_{s} will be released from the nuclei during 30 min of incubation. Since 1 pmol/ml of [\(^{3}I\)]T_{s} is the lowest concentration of T_{s} incubated in vitro, the released endogenous T_{s} will augment by 15% the medium hormone concentration at tracer [\(^{3}I\)]T_{s} levels and will make a progressively smaller contribution to the T_{s} concentration when increasing doses of hormone are incubated. The resulting change in the calculation of bound T_{s} is so small that it is within the error of determination of specific T_{s} binding. Thus, the contribution of endogenous T_{s} to total incubated hormone concentration has been discounted in subsequent calculations.

The release rate of T_{s} bound to nuclear sites was determined both for endogenous hormone and for T_{s} bound during incubation in vitro (Fig. 5). A tracer dose of [\(^{3}I\)]T_{s} (5 ng/100 g body wt) was injected i.v. 30 min before the animals were killed. During this interval the specific nuclear sites are maximally labeled in vivo (2). Nuclei were then harvested and incubated with tracer [\(^{3}I\)]T_{s} (1 pmol/ml). Incubation mixtures were sampled at 2-min intervals to determine specific nuclear binding. At 9.5 min of incubation, the mixtures were divided. A molar excess of T_{s} (3,000 pmol/ml) was added to one portion to prevent detectable further nuclear binding of [\(^{3}I\)]T_{s} from the incubation medium, and the vehicle in which the loading dose was dissolved was added to the other portion. The curves in Fig. 5 show that the release rate of nuclear T_{s} was the same for endogenous T_{s} (t_{1} = 14.0 min) as for T_{s} bound to specific nuclear sites in vitro (t_{1} = 14.5 min). The lack of significant change in the maximal percentage of [\(^{3}I\)]T_{s} bound specifically in vitro when vehicle was added indicated that the vehicle did not perturb the system. In two other experiments, similarly designed, the t_{1} of release of nuclear T_{s} was 10.0 and 12.2 min. The similarity in the rates of release in vitro of T_{s} bound to the nuclear sites in vivo and in vitro provides further evidence that T_{s} binding to isolated nuclei occurs at the same sites as previously reported in studies in vivo.

The average t_{1} of 12 min for T_{s} bound to nuclear sites also allows estimation of the effect of endogenous T_{s} released from the nuclei upon subsequent calculations.

As determined by in vivo displacement studies (4), the mean M is 1.77 ng T_{s} for nuclei derived from 1 g of liver (2.72 pmol/g). In euthyroid rats, the mean percentage saturation of these sites is 47% (4), and the mean recovery of nuclei based on DNA measurements is 59%.

Thus, the nuclear suspensions used in these studies contain approximately 0.151 pmol T_{s}/0.2 g liver nuclei (2.72 × 0.47 × 0.58 × 0.2). Based on the observed release rates, the main portion (82%) of the endogenous T_{s} will be released from the nuclei during 30 min of incubation. Since 1 pmol/ml of [\(^{3}I\)]T_{s} is the lowest concentration of T_{s} incubated in vitro, the released endogenous T_{s} will augment by 15% the medium hormone concentration at tracer [\(^{3}I\)]T_{s} levels and will make a progressively smaller contribution to the T_{s} concentration when increasing doses of hormone are incubated. The resulting change in the calculation of bound T_{s} is so small that it is within the error of determination of specific T_{s} binding. Thus, the contribution of endogenous T_{s} to total incubated hormone concentration has been discounted in subsequent calculations.

The release rate of T_{s} bound to nuclear sites was determined both for endogenous hormone and for T_{s} bound during incubation in vitro (Fig. 5). A tracer dose of [\(^{3}I\)]T_{s} (5 ng/100 g body wt) was injected i.v. 30 min before the animals were killed. During this interval the specific nuclear sites are maximally labeled in vivo (2). Nuclei were then harvested and incubated with tracer [\(^{3}I\)]T_{s} (1 pmol/ml). Incubation mixtures were sampled at 2-min intervals to determine specific nuclear binding. At 9.5 min of incubation, the mixtures were divided. A molar excess of T_{s} (3,000 pmol/ml) was added to one portion to prevent detectable further nuclear binding of [\(^{3}I\)]T_{s} from the incubation medium, and the vehicle in which the loading dose was dissolved was added to the other portion. The curves in Fig. 5 show that the release rate of nuclear T_{s} was the same for endogenous T_{s} (t_{1} = 14.0 min) as for T_{s} bound to specific nuclear sites in vitro (t_{1} = 14.5 min). The lack of significant change in the maximal percentage of [\(^{3}I\)]T_{s} bound specifically in vitro when vehicle was added indicated that the vehicle did not perturb the system. In two other experiments, similarly designed, the t_{1} of release of nuclear T_{s} was 10.0 and 12.2 min. The similarity in the rates of release in vitro of T_{s} bound to the nuclear sites in vivo and in vitro provides further evidence that T_{s} binding to isolated nuclei occurs at the same sites as previously reported in studies in vivo.

The average t_{1} of 12 min for T_{s} bound to nuclear sites also allows estimation of the effect of endogenous T_{s} released from the nuclei upon subsequent calculations.

54 M. I. Surks, D. H. Koerner, and J. H. Oppenheimer
Additionally, since an average of 47% of the nuclear sites are occupied under endogenous conditions, calculations based on the observed release rate of nuclear T₃ indicate that 80–95% of the nuclear sites will be accessible for hormone binding in vitro during a 30-min incubation. Thus, the nuclear binding capacity determined in vitro should reflect adequately that measured in vivo.

**Characterization of T₃ bound to isolated nuclei.** Chromatographic studies were performed to determine the nature of the T₃ bound to isolated nuclei for comparison to previously reported data when nuclei were labeled with [³¹I]T₃ i.v., 50 ng/100 g body wt, 30 min before they were killed. Nuclei were harvested and incubated either with a low dose (1 pmol/ml) or a molar excess (3,000 pmol/ml) [³¹I]T₃ in vitro for 10 min at 37°C. After incubation, one portion was taken for measurement of total nuclear T₃ radioactivity and another was treated with Triton X-100, 0.5% in 0.32 M sucrose and 3 mM MgCl₂. Pelleted nuclei from a third and fourth portion were treated separately with buffered 0.14 M NaCl or 0.4 M KCl. As indicated in Table II, 50.2–59.5% of the nuclear [³¹I]T₃ bound in vivo remained with the nuclei after incubation with either a low or high dose of T₃. In contrast, the 22.1% of [³¹I]T₃ bound to nuclei in vitro after incubation with a tracer dose of [³¹I]T₃ and the 16.2% upon incubation with a molar excess of [³¹I]T₃ was substantially decreased by Triton X-100 treatment to 7.4 and 1.2% of the added [³¹I]T₃, respectively.

**Table II**

**Extraction by Buffered 0.14 M NaCl or 0.4 M KCl of Nuclear T₃ Bound after in Vivo Injection of [³¹I]T₃, Followed by in Vitro Incubation with [³¹I]T₃**

<table>
<thead>
<tr>
<th>Source of radioactive T₃ bound to nuclei</th>
<th>Treatment</th>
<th>In vitro incubation</th>
<th>In vivo injection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Low dose</td>
<td>High dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None (total binding)</td>
<td></td>
<td>22.1</td>
<td>16.2</td>
</tr>
<tr>
<td>0.5% Triton, 0.32 M sucrose</td>
<td></td>
<td>7.4</td>
<td>1.2</td>
</tr>
<tr>
<td>Extracted radioactivity, % of nuclear radioactivity</td>
<td></td>
<td>12.8</td>
<td>15.0</td>
</tr>
<tr>
<td>0.14 M NaCl, 10 mM Tris, pH 7.8</td>
<td></td>
<td>52.7</td>
<td>43.1</td>
</tr>
<tr>
<td>0.4 M KCl, 10 mM Tris, pH 8.0</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Endogenous nuclear T₃ was labeled in vivo by injection of [³¹I]T₃, 50 ng/100 g body wt, 30 min before rats were killed. After isolation, the nuclei were incubated in vitro with either a low (1.0 pmol/ml) or high dose (3,000 pmol/ml) [³¹I]T₃ for 10 min at 37°C. The values presented are representative of three experiments. The small difference between the percentage of initial [³¹I]T₃ recovered in the nuclei is not significant statistically.

**Figures 6**

Sephadex G-50 chromatography of 0.4 M KCl extracts of nuclei incubated in vitro with tracer [³¹I]T₃ (1 pmol/ml) or a large dose (3,000 pmol/ml) of [³¹I]T₃. 0.5 ml nuclear extract was applied, and 1-ml fractions were collected. The arrow designates the void volume as determined by the elution of dextran Blue. Recovery of applied counts was between 90–110%.

Extraction of the incubated nuclei with 0.14 M NaCl buffered at pH 7.5 removed 13–15% of the [³¹I]T₃ bound in vitro and a smaller fraction of the [³¹I]T₃ bound in vivo. Upon filtration of these extracts on small Sephadex G-50 columns, 97–99% of the applied radioactivity eluted as free hormone.

Treatment with 0.4 M KCl buffered at pH 8.0 extracted 47–53% of the nuclear [³¹I]T₃ bound in vitro and 41–43% of the in vivo-bound [³¹I]T₃. Consonant with previous studies (5), 80% of the [³¹I]T₃ bound specifically to the nuclei in vivo appeared in the void volume and was considered protein-bound. The elution profiles of the 0.4 M KCl extracts of [³¹I]T₃ bound to the nuclei in vitro are illustrated in Fig. 6. After incubation with a low dose of T₃, 37% of the KCl-extractable [³¹I]T₃ eluted in the void volume (protein-bound). The remainder eluted as free or nonprotein-bound hormone.

After incubation with a molar excess of T₃, virtually all of the KCl-extractable [³¹I]T₃ eluted as free hormone. The nuclear radioactivity in the 0.4 M KCl extracts, the 0.14 M NaCl extracts, the unextracted nuclei, and the Triton X-100-treated nuclei was shown to be authentic T₃ by paper chromatographic procedures.

Since an appreciable amount (37%) of the [³¹I]T₃ bound to specific nuclei sites in vitro was recovered as protein-bound hormone, this extract was analyzed in greater detail on a Sephadex G-100 column (Fig. 7). The [³¹I]T₃ incorporated in vivo showed an elution profile virtually identical to that reported previously (5). The large peak of radioactivity observed at the void volume could represent either T₃ protein complex still in association with DNA or aggregates of the T₃ nucleoprotein complex. A second peak observed at tube 29 is T₃ bound to nucleoprotein. If its structure is globular, the molecular weight of this protein, determined by comparison to the elution profiles of marker proteins.
with known molecular weights, was 60–65,000, as observed previously (5). The remainder of the radioactivity eluted after tube 100 and represented free hormone. An almost identical elution profile was observed for the $^{125}$I-Ts bound to nuclear sites in vitro. The distribution of radioactivity among the peaks was somewhat different, however, with a greater fraction of radioactivity appearing as free hormone. This is probably due to the fact that treatment with 0.4 M KCl extracts some $^{125}$I-Ts bound nonspecifically as well as that bound to specific sites during in vitro incubation (Table II). This would not occur when the nuclear sites were labeled in vivo, since only 10% of the nuclear Ts is bound nonspecifically after injection of a tracer dose of Ts (1, 2). The virtual identity of the elution profiles of in vivo and in vitro-bound nuclear Ts suggests that Ts is bound by isolated nuclei to the same chromatin-associated non-histone protein as previously shown for endogenous Ts in vivo (5).

**Apparent equilibrium association constant and binding capacity.** After it was established that equilibrium conditions prevailed when nuclei were incubated at 37°C for 30 min, displacement studies, as depicted in Fig. 1, were plotted according to Scatchard to determine the apparent $K_s$ for the specific nuclear sites and Ts, and the nuclear binding capacity ($M$) (Fig. 8). These plots revealed a single class of specific nuclear binding sites for Ts. In the illustrated experiment, carried out with unwashed nuclei incubated in the presence of 0.3% HSA, $K_s = 4.28 \times 10^6$ M$^{-1}$. Mean $K_s$ for 13 studies performed under these conditions was $5.55 \times 10^6$ M$^{-1}$ (range = 1.9–12.3 $\times$ 10$^6$ M$^{-1}$) (Table III). The possibility that another class of binding sites with a higher affinity for Ts might have been overlooked is unlikely, since no significant change in $K_s$ or $M$ was noted in several studies in which the tracer dose of $^{125}$I-Ts was reduced to 0.1 or 0.01 pmol/ml. HSA was employed to insure solubility of the higher doses of Ts in the incubation medium. Since it was possible, however, that the added 0.3% HSA might extensively bind the Ts in the incubation buffer, the free Ts concentration in the incubation buffer might be overestimated, and the calculated $K_s$ from Scatchard plots underestimated. This possibility was considered unlikely, since the $K_s$ was not significantly different from the $K_s$ of the 0.3% HSA incubation in studies in which either unwashed nuclei were incubated in buffer supplemented by a 10-fold lower HSA concentration (0.03%) or washed nuclei were incubated in buffer without addition of exogenous protein (Table III). The degree of protein binding of Ts was also studied by equilibrium dialysis. The dialysis fraction of incubation buffer with tracer $^{125}$I-Ts supplemented with 0.3% HSA was 0.84, and that of 0.3% HSA alone was 0.87. These studies showed that, at most, only 16% of Ts in the incubation medium could be protein-bound. Thus, $K_s$ determined by these methods was not significantly influenced by protein binding of Ts in the incubation medium.

The Scatchard plots of these incubations also enabled estimation of the $M$ of the nuclear sites for Ts. Mean $M$ for 19 experiments was $0.23 \times 10^6$ M (Table III) and was equivalent to 0.3–0.5 ng Ts/ng DNA. The $M$ determined in these experiments was in good agreement with that anticipated for the nuclear receptor sites from measurements of $M$ in in vivo displacement studies (4). The mean $M$ in in vivo studies is 1.77 ng Ts for nuclei derived from 1 g liver (range = 1.02–2.35 ng/g). Since the mean recovery of hepatic nuclei isolated by centrifugation through 2.2 M sucrose is 59%, a mean M of 1.04 ng Ts/g liver nuclei (range = 0.60–1.37 ng Ts/g) would be anticipated in vitro. Mean M isolated was 0.85 ng Ts/g isolated liver nuclei (range = 0.46–1.30 ng/g) for all experimental conditions. The modest reduction in binding capacity in washed nuclei may result from a small decrease in the recovery of nuclei during the washing procedures. The agreement in M determined in vitro with that predicted from measurements in vivo provides further evidence that the nuclear Ts binding site studied in vitro is probably the same as in the intact animal.

**Role of cytosol protein.** A significant role for specific cytosol proteins in effecting the translocation of Ts from the incubation medium to the nuclear receptor site was considered unlikely, since nuclear binding of Ts to sites quantitatively and physicochemically similar to those

---

*Most of these determinations were performed in the course of other investigations.*
studied in vivo could readily be demonstrated in vitro. Nevertheless, the possibility existed that a small amount of cytosol protein contaminating the isolated nuclear pellet might be critical for nuclear binding in vitro. In a representative experiment, the total protein content of hepatic nuclei recovered from 0.2 g liver was 1.780 mg. After suspension in 1 ml incubation medium, nearly 10% of the nuclear protein, 0.166 mg, was found in the medium as soluble protein. The nuclear protein at the start of incubation was 1.614 mg (1.780-0.166). After a 30-min incubation at 37°C, the protein content of the incubation medium increased to 0.212 mg. Thus, only 0.046 mg or 2.8% [(0.212 - 0.166)/1.614] × 100 of the initial nuclear protein was released during incubation. We considered, therefore, that the major portion of the protein found in the incubation medium at the start of incubation might be cytosol protein contaminating the nuclear pellet. The potential role of such cytosol contamination in nuclear binding was assessed in experiments employing nuclei extensively washed before incubation. In one study, $K_s$ of nuclei incubated in buffer alone was $1.5 \times 10^9 M^{-1}$. Addition of the protein recovered from the supernate of the nuclear washes ("contaminating cytosol") at a concentration of 0.11 mg/ml did not result in any change in $K_s$. Similar results were obtained for nuclei incubated with or without washing after a 30-min preincubation at 37°C. In a third experiment, $K_s$ for extensively washed nuclei and $T_3$ was $1.70 \times 10^9 M^{-1}$. Addition of separately isolated hepatic cytosol to the incubation medium at a concentration of 1 mg/ml resulted in a minimal change in $K_s$ to $1.53 \times 10^9 M^{-1}$. Finally, a single batch of nuclei was divided, one portion being extensively washed and the other simply resuspended in incubation medium containing contaminating cytosol protein. The $K_s$ was $6.2 \times 10^9 M^{-1}$ and $8.0 \times 10^9 M^{-1}$ and $M$ was $0.16 \times 10^9 M$ and $0.14 \times 10^9 M$, respectively. Thus no significant changes in nuclear binding resulted from extensive washing.

Since nuclei isolated from euthyroid rats were used in all of these studies, it remained possible that endogenous $T_3$ bound to specific cytosol proteins required for translocation of $T_3$ to the nuclear receptor site were already present within the nuclei at the start of incubation. These proteins might then be released into the medium during incubation, bind exogenous $T_3$, and transport the hormone back into the nucleus to the receptor site in vitro. If this formulation were correct, it would not be possible to demonstrate specific nuclear binding in vitro when nuclei isolated from athyreotic rats were used. In such nuclei there is no $T_3$ bound to the nuclear receptor site at the beginning of incubation. Fig. 9 illustrates a Scatchard plot of an in vitro displacement study employing nuclei obtained from athyreotic rats. The calculated $K_s$ and $M$ are in the range of these parameters measured in nuclei from euthyroid animals (Table III). In the study illustrated, the $K_s$ was $4.27 \times 10^9 M^{-1}$, and $M$ was $0.35 \times 10^9 M$ (1.14 ng/g liver nuclei). Thus, the demonstration of specific binding of $T_3$ by isolated nuclei from athyreotic rats suggests that the existence of intranuclear cytosol protein that facilitates $T_3$ translocation is unlikely.

**DISCUSSION**

Since many effects of iodothyronines reported in vitro have subsequently been shown to be unrelated to physio-

**TABLE III**

*Apparent $K_s$ and Binding Capacity ($M$) for Isolated Hepatic Nuclei Incubated with $T_3$ under Different Conditions*

<table>
<thead>
<tr>
<th>Incubation conditions</th>
<th>$n$</th>
<th>$K_s$</th>
<th>$M$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$\times 10^9 M^{-1}$</td>
<td>$\times 10^9 M$</td>
</tr>
<tr>
<td>Unwashed nuclei</td>
<td>13</td>
<td>5.55</td>
<td>0.22</td>
</tr>
<tr>
<td>+0.3% HSA</td>
<td></td>
<td>(1.9-12.3)</td>
<td>(0.13-0.40)</td>
</tr>
<tr>
<td>Unwashed nuclei</td>
<td>2</td>
<td>3.10</td>
<td>0.33</td>
</tr>
<tr>
<td>+0.03% HSA</td>
<td></td>
<td>(2.3-3.9)</td>
<td>(0.28-0.38)</td>
</tr>
<tr>
<td>Washed nuclei</td>
<td>4</td>
<td>3.48</td>
<td>0.21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(2.1-4.5)</td>
<td>(0.11-0.36)</td>
</tr>
</tbody>
</table>

Unwashed nuclei were isolated through 2.2 M sucrose and 3 mM MgCl$_2$ and resuspended in incubation buffer. Washed nuclei were similarly isolated but suspended in 0.3 M sucrose, 3 mM MgCl$_2$, and resuspended by centrifugation three times before incubation in incubation buffer. The numbers in parentheses indicate the range of values. A 20% suspension of nuclei were incubated in all experiments except three in the 0.3% HSA group, in which a 10% suspension was used.

![Figure 8](image)  
**Figure 8** Scatchard plot of $T_3$ bound to specific sites of isolated hepatic nuclei in vitro. In this experiment, nuclei were incubated directly after isolation without further purification in the presence of 0.3% HSA. $M = 0.42 \times 10^9 M^{-1}$, equivalent to 1.37 ng $T_3$ per g liver nuclei. $K_s$ is $4.28 \times 10^9 M^{-1}$. 

*Triiodothyronine Binding to Nuclear Receptors in Vitro* 57
logical events in the intact animal, a major focus of the current studies has been to assess the relevance of T₃ binding to nuclei in vitro to nuclear binding of endogenous T₃ in vivo (1, 2). Thus, after the initial demonstration of specific T₃ binding to limited-capacity high-affinity sites in isolated hepatic nuclei (11, 12), considerable effort was expended to ascertain whether nuclear binding of T₃ in vitro occurred at the same site as endogenous T₃ in the intact rat. Separate lines of evidence indicate that this is indeed the case. First, the concentration of nuclear sites determined in vitro, 0.23 × 10⁶ M, was virtually indistinguishable from the concentration of nuclear T₃ binding sites reported in vivo (2, 4), when corrected for recovery of nuclei during the isolation procedures. Similar results had been reported in separate studies by Samuels and Tsai (12). From published in vivo data, the predicted nuclear T₃ binding capacity in vitro was 1.04 ng T₃ (range 0.60–1.37) for nuclei derived from 1 g of liver or 0.48 ng T₃/mg DNA. The binding capacity observed in the present studies was 0.85 ng T₃ (range 0.46–1.30)/g liver nuclei (0.30–0.71 ng T₃/mg DNA), values not significantly different from those predicted. Second, T₃ bound to the nuclear sites in vitro and endogenous T₃ labeled in vivo were released from the nuclear sites at the same rate in vitro. The kinetics of in vitro nuclear binding indicate that the in vitro incubation system does not conform to a simple two-compartmental model. Calculation of the rate constants suggests that the rate constant of T₃ binding to the nuclear receptor is several orders of magnitude too small to be compatible with a Kₛ in the range of 10⁶ M⁻¹. An unknown nuclear compartment, perhaps the nuclear outer membrane, appears to delay translocation of T₃ from the incubation buffer to specific sites within the nuclei. Third, the physical characteristics of the nuclear T₃ binding sites demonstrated in vitro appear identical to the reported characteristics of the nuclear T₃ binding site in vivo (5). Thus, T₃ bound to the nuclear site in vitro resists extraction by low salt solutions but is solubilized readily by treatment with 0.4 M KCl buffered at pH 8.0. The column chromatographic studies of the extracted T₃ indicate that binding occurs to a protein with the same apparent molecular weight, if the protein is globular, as observed in in vivo studies, and suggest that the extracted hormone, similar to endogenous T₃, appears bound to a chromatin-associated nonhistone protein. Fourth, the structural requirements for nuclear binding in vitro appear strikingly similar to those for nuclear binding in vivo. This has been demonstrated by measurements of the capacity of a series of iodothyronine analogues to compete with T₃ for the nuclear sites. Data demonstrating similar avidity of nuclear sites for a series of T₃ analogues has been reported previously both in intact animals (3) and in the in vitro incubation system (11).

The only difference observed between T₃ binding by nuclei in vitro and T₃ binding in vivo is that the binding affinity of the nuclear sites was substantially lower (1,000-fold) in vitro than in the living animal (2). The current studies show that specific nuclear binding in vitro does not depend on active metabolic processes, since T₃ binding was unaffected by addition of different metabolic inhibitors. The difference in binding affinity, therefore, probably results from conditions of incubation of the isolated nuclei vastly different from the intracellular milieu. In this regard, a sixfold decrease in binding affinity but no change in total sites has been reported by Samuels and Tsai (12) for T₃ binding by nuclei isolated from cultured pituitary GH cells and rat liver, compared to T₃ binding by nuclei in intact GH cells and human lymphocytes (10). Thus, the bulk of evidence indicates that in vitro binding of T₃ occurs at the same chromatin protein site as endogenous hormone. The ability to study nuclear-T₃ interactions in vitro should facilitate a detailed analysis of this process.

Although it is clear that the T₃ receptor is a chromatin-associated nonhistone protein, which can be demonstrated both in vivo and in vitro, the mechanism by which T₃ enters the nucleus from the cytosol and binds to the receptor remains obscure. The present studies show that active metabolic processes are not required for binding to nuclear sites. That the translocation of

---

**Figure 9** Scatchard plot of T₃ bound to specific sites of isolated nuclei obtained from athyreotic rats. The isolated nuclei were further purified by three washing procedures, as described in Methods, and incubated without the addition of exogenous protein. M = 0.35 × 10⁶ M (1.14 ng T₃/g liver nuclei). Kₛ is 4.27 × 10⁶ M⁻¹.
steroid hormones to chromatin receptor sites appears to require initial binding to specific cytosol proteins, which are translocated into the nucleus and bind to the chromatin, raises the question whether analogous events obtain for Ts. Cytosol proteins that bind both Ts and L-thyroxine have been reported previously from a number of laboratories (19–23), but the role of these proteins in effecting the translocation of Ts to the nucleus was not studied by these investigators. Recently, Dillman, Surks, and Oppenheimer (24) have compared the quantitative aspects of binding of Ts and iodothyronine analogues by cytosol proteins to those of the nuclear receptor sites. Although a class of limited-capacity, high-affinity binding sites for Ts was demonstrated in the cytosol, marked differences were observed between these sites and those of the nuclear receptor. The apparent association constant for cytosol Ts binding sites was approximately 1/200th that of the nucleus, and the binding capacity of the cytosol Ts binding sites was nearly 250 times that of the nuclear sites. Moreover, less than 1% of the cytosol sites were saturated, compared to 47% saturation of nuclear sites at euthyroid endogenous Ts concentrations (4). Furthermore, the spectrum of binding affinities of the cytosol sites for Ts analogues was grossly different from that of the nuclear receptor. Thus, unless radical changes occur in the quantitative and qualitative binding characteristics of cytosol proteins upon entry into the nucleus, these major differences between cytosol protein and nuclear receptor binding of Ts suggested that an interaction between Ts and specific cytosol proteins was not a prerequisite for binding of Ts to the nuclear receptor. The present studies, which demonstrate that Ts is translocated in vitro from an aqueous medium to nuclear sites that are qualitatively and quantitatively similar to the nuclear receptor sites of the intact rat, strongly support this conclusion. Addition of small amounts of cytosol protein did not enhance translocation of Ts into the nucleus. In contrast, incubation of isolated nuclei directly in cytosol decreased nuclear binding (11). Finally, the possibility was tested that intranuclear Ts bound to a specific cytosol protein was already present in the isolated nuclei and then acted like a shuttle, binding hormone at the nuclear membrane and transporting it to the chromatin receptor. This possibility appears quite unlikely since the Ts binding characteristics in vitro for nuclei obtained from athyreotic rats were similar in all respects to those obtained from euthyroid animals.

Thus, in contrast to steroid hormones, Ts does not appear to require an initial interaction with a specific cytosol protein to effect translocation into the nucleus. A different provisional model for nuclear Ts binding may then be proposed. Ts bound to plasma proteins exchanges rapidly with cytosol proteins and cellular organelles. Once in the cell, bound Ts readily dissociates and either returns to the plasma compartment or may be translocated into the nucleus as free hormone with subsequent binding to the chromatin nonhistone receptor. Binding to the receptor may then result in an increased rate of transcription of DNA or the transcription of new DNA loci, which eventuate in the expression of hormone action.

ACKNOWLEDGMENTS

The authors thank Mr. Jose Guerra for his expert technical assistance and Ms. Geraldine Monica and Mary Ann Mullen for their secretarial support. Mr. Barry Shapiro drew the illustrations.

This work was supported in part by NIH grant AM 15421-14, NIH grant CA 16463-01, and Department of the Army contract DA-49-193-MD-2967.

REFERENCES


